CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 444 filers reported holding CRISPR THERAPEUTICS AG in Q1 2022. The put-call ratio across all filers is 0.99 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,305 | -23.3% | 72,830 | -5.1% | 0.01% | -22.2% |
| Q2 2023 | $4,310 | +15.3% | 76,763 | -7.1% | 0.01% | 0.0% |
| Q1 2023 | $3,737 | -1.5% | 82,626 | -11.5% | 0.01% | -10.0% |
| Q4 2022 | $3,794 | -99.9% | 93,341 | +17.8% | 0.01% | -33.3% |
| Q3 2022 | $5,180,000 | -32.5% | 79,257 | -37.2% | 0.02% | -25.0% |
| Q2 2022 | $7,673,000 | +7.2% | 126,259 | +10.7% | 0.02% | +33.3% |
| Q1 2022 | $7,160,000 | -9.2% | 114,061 | +9.6% | 0.02% | -16.7% |
| Q4 2021 | $7,884,000 | -26.9% | 104,046 | +8.0% | 0.02% | -33.3% |
| Q3 2021 | $10,785,000 | -36.0% | 96,352 | -7.5% | 0.03% | -32.5% |
| Q2 2021 | $16,862,000 | +16.2% | 104,159 | -12.5% | 0.04% | +2.6% |
| Q1 2021 | $14,510,000 | – | 119,081 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $27,989,046 | 33.20% |
| Gilfoyle Management LLC | 100 | $4,842 | 15.90% |
| NEA Management Company, LLC | 1,587,854 | $89,142,124 | 6.80% |
| ARK Investment Management | 7,338,447 | $411,980,394 | 2.73% |
| Nikko Asset Management Americas, Inc. | 3,533,357 | $198,327,328 | 2.09% |
| Del-Sette Capital Management, LLC | 33,661 | $1,889,729 | 1.79% |
| Ikarian Capital, LLC | 200,000 | $11,228,000 | 1.79% |
| Ikarian Capital, LLC | 200,000 | $11,228,000 | 1.79% |
| Merlin Capital, Inc | 8,802 | $494,144 | 1.67% |
| Green Alpha Advisors, LLC | 34,373 | $1,929,700 | 1.27% |